155 related articles for article (PubMed ID: 32394511)
1. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia.
Maes MS; Lu JY; Tiwari AK; Freeman N; de Luca V; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Drug Dev Res; 2021 Aug; 82(5):678-684. PubMed ID: 32394511
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
3. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.
Loonen AJ; Wilffert B; Ivanova SA
Pharmacogenomics; 2019 Nov; 20(17):1199-1223. PubMed ID: 31686592
[TBL] [Abstract][Full Text] [Related]
4. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
[TBL] [Abstract][Full Text] [Related]
5. Association study between the neurexin-1 gene and tardive dyskinesia.
Lanning R; Lett TA; Tiwari AK; Brandl EJ; de Luca V; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Remington G; Kennedy JL; Zai CC
Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120489
[TBL] [Abstract][Full Text] [Related]
6. Liver enzyme
Lu JY; Tiwari AK; Freeman N; Zai GC; Luca V; Müller DJ; Tampakeras M; Herbert D; Emmerson H; Cheema SY; King N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Pharmacogenomics; 2020 Oct; 21(15):1065-1072. PubMed ID: 32969762
[No Abstract] [Full Text] [Related]
7. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
[TBL] [Abstract][Full Text] [Related]
8. Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia.
Hui L; Han M; Yin GZ; Zhang Y; Huang XF; Qian ZK; Gu WG; Gu XC; Zhu XM; Soares JC; Ning Y; Zheng Y; Du XD; Zhang XY
Schizophr Res; 2017 Apr; 182():104-109. PubMed ID: 27776953
[TBL] [Abstract][Full Text] [Related]
9. Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia.
Zai CC; Tiwari AK; Chowdhury NI; Yilmaz Z; de Luca V; Müller DJ; Potkin SG; Lieberman JA; Meltzer HY; Voineskos AN; Remington G; Kennedy JL
World J Biol Psychiatry; 2019 Jan; 20(1):91-95. PubMed ID: 28394697
[TBL] [Abstract][Full Text] [Related]
10. Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects.
Punchaichira TJ; Mukhopadhyay A; Kukshal P; Bhatia T; Deshpande SN; Thelma BK
J Psychopharmacol; 2020 Mar; 34(3):358-369. PubMed ID: 31913053
[TBL] [Abstract][Full Text] [Related]
11. Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.
Lai IC; Mo GH; Chen ML; Wang YC; Chen JY; Liao DL; Bai YM; Lin CC; Chen TT; Liou YJ
Eur J Clin Pharmacol; 2011 Apr; 67(4):383-388. PubMed ID: 21181138
[TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
13. Genome wide study of tardive dyskinesia in schizophrenia.
Lim K; Lam M; Zai C; Tay J; Karlsson N; Deshpande SN; Thelma BK; Ozaki N; Inada T; Sim K; Chong SA; Lencz T; Liu J; Lee J
Transl Psychiatry; 2021 Jun; 11(1):351. PubMed ID: 34103471
[TBL] [Abstract][Full Text] [Related]
14. Associations between polymorphisms in the cannabinoid receptor 1 gene, cognitive impairments and tardive dyskinesia in a Chinese population with schizophrenia.
Lu C; Li S; Li Y; Zhang X; Chi J; Jiang Q; Ma Y; Shi X; Wang L; Li J
Brain Res; 2023 Dec; 1821():148579. PubMed ID: 37739333
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia.
Voisey J; Swagell CD; Hughes IP; Lawford BR; Young RM; Morris CP
Eur Psychiatry; 2010 Oct; 25(6):314-9. PubMed ID: 20615671
[TBL] [Abstract][Full Text] [Related]
16. Single point mutation on the gene encoding dysbindin results in recognition deficits.
Chang EH; Fernando K; Yeung LWE; Barbari K; Chandon TS; Malhotra AK
Genes Brain Behav; 2018 Jun; 17(5):e12449. PubMed ID: 29227583
[TBL] [Abstract][Full Text] [Related]
17. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene.
Duan J; Martinez M; Sanders AR; Hou C; Burrell GJ; Krasner AJ; Schwartz DB; Gejman PV
Hum Hered; 2007; 64(2):97-106. PubMed ID: 17476109
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
19. Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic Polymorphisms.
Uludag K; Wang DM; Zhang XY
Oxid Med Cell Longev; 2022; 2022():5748924. PubMed ID: 36338339
[TBL] [Abstract][Full Text] [Related]
20. Genetics of tardive dyskinesia: Promising leads and ways forward.
Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
